---
title: "SYNERGY: The raw material drug Amlodipine Besylate has passed the GMP compliance inspection"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/252990104.md"
description: "SYNERGY announced that its raw material drug, Mesalazine Potassium, has passed the GMP compliance inspection, which is beneficial for the company to expand the sales of its products in the domestic market, forming a good pattern of simultaneous sales in both domestic and foreign markets. Mesalazine Potassium is suitable for the treatment of adult primary hypertension"
datetime: "2025-08-14T08:22:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/252990104.md)
  - [en](https://longbridge.com/en/news/252990104.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/252990104.md)
generator: "portal-rs"
---

# SYNERGY: The raw material drug Amlodipine Besylate has passed the GMP compliance inspection

SYNERGY announced that the company's raw material drug Mesalazine Potassium has passed the drug GMP compliance inspection, which is beneficial for the company to expand the product's sales in the domestic market, forming a good pattern of simultaneous sales in both domestic and foreign markets. Mesalazine Potassium is suitable for the treatment of adult primary hypertension

### Related Stocks

- [300636.CN](https://longbridge.com/en/quote/300636.CN.md)

## Related News & Research

- [Alibaba’s AI Spending Spree Intensifies — Surprise Stock Sale Has Analysts Asking Why](https://longbridge.com/en/news/296767766.md)
- [Promise Analyzes Telehealth Licensing Rules as Compact Hits Record 3,633 Licenses in a Month](https://longbridge.com/en/news/296635882.md)
- [Livzon Pharma buys 3.5% Xinbeijiang Pharma stake for RMB 106.7 million](https://longbridge.com/en/news/296601614.md)
- [Dino Polska S.A. (WSE:DNP) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year](https://longbridge.com/en/news/296763667.md)
- [08:36 ETUltimate Men's HQ Launches Private Product-Match Education Experience](https://longbridge.com/en/news/296789283.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**